Still, in node-negative colon cancer, a group with generally good prognosis, some develop disease recurrence; determining both tumor–stroma ratio (TSR) and BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutations might help in prognostication (17). The gene discussed is BRAF; the disease is neoplasm.